Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.
Cutter G, Veneziano A, Grinspan A, Al-Banna M, Boyko A, Zakharova M, Maida E, Pasic MB, Gandhi SK, Everts R, Cordioli C, Rossi S. Cutter G, et al. Among authors: grinspan a. Mult Scler Relat Disord. 2020 May;40:101957. doi: 10.1016/j.msard.2020.101957. Epub 2020 Jan 20. Mult Scler Relat Disord. 2020. PMID: 32028117 Clinical Trial.
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).
Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA; TRANSFORMS Study Group. Khatri BO, et al. Among authors: grinspan a. Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12. Mult Scler Relat Disord. 2014. PMID: 25876473
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.
Kremenchutzky M, O'Connor P, Hohlfeld R, Zhang-Auberson L, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Kappos L. Kremenchutzky M, et al. Among authors: grinspan a. Mult Scler Relat Disord. 2014 May;3(3):341-9. doi: 10.1016/j.msard.2013.10.006. Epub 2013 Nov 5. Mult Scler Relat Disord. 2014. PMID: 25876471 Free article.
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Kolitz S, Hasson T, Towfic F, Funt JM, Bakshi S, Fowler KD, Laifenfeld D, Grinspan A, Artyomov MN, Birnberg T, Schwartz R, Komlosh A, Hayardeny L, Ladkani D, Hayden MR, Zeskind B, Grossman I. Kolitz S, et al. Among authors: grinspan a. Sci Rep. 2015 May 22;5:10191. doi: 10.1038/srep10191. Sci Rep. 2015. PMID: 25998228 Free PMC article.
Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group.
Glauser TA, Nigro M, Sachdeo R, Pasteris LA, Weinstein S, Abou-Khalil B, Frank LM, Grinspan A, Guarino T, Bettis D, Kerrigan J, Geoffroy G, Mandelbaum D, Jacobs T, Mesenbrink P, Kramer L, D'Souza J. Glauser TA, et al. Among authors: grinspan a. Neurology. 2000 Jun 27;54(12):2237-44. doi: 10.1212/wnl.54.12.2237. Neurology. 2000. PMID: 10881246 Clinical Trial.
Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database.
Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, Riley C, Ross AP, Baruch P, Drillman T, Coyle PK. Sandberg-Wollheim M, et al. Among authors: grinspan a. Int J MS Care. 2018 Jan-Feb;20(1):9-14. doi: 10.7224/1537-2073.2016-079. Int J MS Care. 2018. PMID: 29507538 Free PMC article.
57 results